Next Article in Journal
Pharmacological Inhibition of Protein Kinase C Reduces West Nile Virus Replication
Previous Article in Journal
The Alphavirus Exit Pathway: What We Know and What We Wish We Knew
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Viruses 2018, 10(2), 90;

Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy

Discipline of Bioscience and Biomedical Engineering, Indian Institute of Technology Indore, Indore, MP 453 552, India
Department of Pharmacology and Experimental Neurosciences, University of Nebraska Medical Center, Omaha, NE 68130, USA
Authors to whom correspondence should be addressed.
Received: 1 December 2017 / Revised: 12 February 2018 / Accepted: 15 February 2018 / Published: 23 February 2018
(This article belongs to the Section Animal Viruses)
Full-Text   |   PDF [999 KB, uploaded 23 February 2018]   |  


Modern oncotherapy approaches are based on inducing controlled apoptosis in tumor cells. Although a number of apoptosis-induction approaches are available, site-specific delivery of therapeutic agents still remain the biggest hurdle in achieving the desired cancer treatment benefit. Additionally, systemic treatment-induced toxicity remains a major limiting factor in chemotherapy. To specifically address drug-accessibility and chemotherapy side effects, oncolytic virotherapy (OV) has emerged as a novel cancer treatment alternative. In OV, recombinant viruses with higher replication capacity and stronger lytic properties are being considered for tumor cell-targeting and subsequent cell lysing. Successful application of OVs lies in achieving strict tumor-specific tropism called oncotropism, which is contingent upon the biophysical interactions of tumor cell surface receptors with viral receptors and subsequent replication of oncolytic viruses in cancer cells. In this direction, few viral vector platforms have been developed and some of these have entered pre-clinical/clinical trials. Among these, the Vesicular stomatitis virus (VSV)-based platform shows high promise, as it is not pathogenic to humans. Further, modern molecular biology techniques such as reverse genetics tools have favorably advanced this field by creating efficient recombinant VSVs for OV; some have entered into clinical trials. In this review, we discuss the current status of VSV based oncotherapy, challenges, and future perspectives regarding its therapeutic applications in the cancer treatment. View Full-Text
Keywords: oncolytic virus; vesicular stomatitis virus (VSV); oncotherapy; tumor lysis; apoptosis oncolytic virus; vesicular stomatitis virus (VSV); oncotherapy; tumor lysis; apoptosis

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Bishnoi, S.; Tiwari, R.; Gupta, S.; Byrareddy, S.N.; Nayak, D. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy. Viruses 2018, 10, 90.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top